Juan Manuel S.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase I Study of Iberdomide and CC-98282 in Combination with R-CHOP21 for Untreated Aggressive B-Cell Lymphoma
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Phase 2 Study on Epcoritamab Monotherapy or Combined with Lenalidomide for Anthracycline-Ineligible Diffuse Large B-Cell Lymphoma Patients
Data & Insights
Has run more than one trial at 269 of 434 partner sites.
Specializations
B-Cell Lymphoma Research
Leading investigations into various forms of B-cell lymphomas, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Research focuses on both newly diagnosed and relapsed/refractory cases.
- DLBCL Treatment Development
- Novel Therapeutic Combinations
- First-line Treatment Strategies
Advanced Treatment Approaches
Specialized in evaluating innovative therapeutic combinations involving monoclonal antibodies, including rituximab, obinutuzumab, and emerging agents like epcoritamab and glofitamab.
- Antibody-Based Therapies
- Combination Treatment Protocols
- Safety and Efficacy Studies
Specialized Lymphoma Focus
Expertise in treating complex lymphoma subtypes, including mantle cell lymphoma and marginal zone lymphoma. Particular interest in developing targeted therapies for relapsed/refractory disease states.
- Rare Lymphoma Variants
- Treatment-Resistant Cases
- Novel Drug Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.